Latest in News & Research
Intervention for Children of Skin Cancer Survivors Can Improve Sun-Protective Behaviors
Minibeam Radiotherapy Promising for Cutaneous, Soft Tissue Malignancies
Poorer Maternal Diet Quality Linked to Infantile Colic, Eczema
1990 to 2023 Saw Increase in Global Burden of Acne
Spatial Frequency Domain Imaging Offers Noninvasive Measure in Systemic Sclerosis
LAUNCH ALERT: FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
CLICK HERE to watch Dr James Del Rosso provide an in-depth overview of Nemluvio (nemolizumab) for atopic dermatitis
LAUNCH ALERT: Positive Results Released from LEVEL UP Trial Comparing Upadacitinib and Dupilumab for Atopic Dermatitis
Upadacitinib outperforms dupilumab in achieving superior efficacy for atopic dermatitis
LAUNCH ALERT: FDA Expands Approval of Klisyri for Broader Actinic Keratosis Treatment
The expanded indication increases the treatment area on the face and scalp from 25 cm2 to 100 cm2
LAUNCH ALERT: FDA Approves VTAMA (Tapinarof) Cream for Atopic Dermatitis
CLICK HERE to watch Dr James Del Rosso give his expert clinical insights on VTAMA for atopic dermatitis
FDA expands ZORYVE (roflumilast) cream 0.3% indication to children as young as 2 years with plaque psoriasis
James Q. Del Rosso, DO, reviews the FDA approval, supporting clinical data, and what this expanded indication means for pediatric plaque psoriasis management.
LAUNCH ALERT: Bimzelx Approved For Moderate-to-Severe Plaque psoriasis
The groundbreaking injectable biologic agent demonstrates unprecedented efficacy in the treatment of psoriasis.
NEWS ALERT: Understanding AhR Agonism in Atopic Dermatitis and Psoriasis
Why understanding a newer mechanism can help clinicians determine where it fits in patient care
When CSU Is Still in Control
In CSU, fewer hives do not always mean better control, especially when patients have learned to live around persistent itch, flares, and disruption.
Chronic Immune-Related AEs Common in Patients With Melanoma Receiving Anti-PD-1 Therapy
EADV: Autonomous AI Can Increase Clinical Capacity for Dermatologists
Lower Dietary Diversity in First Year Linked to Atopic Dermatitis
Atopic Dermatitis and What Familiarity Can Miss
At Fall Clinical 2026, familiar presentations of atopic dermatitis invite another look at diagnosis, burden, and the point when the usual approach stops being...
IBD Events Rare in Patients With Hidradenitis Suppurativa Treated With IL-17 Inhibitors, Placebo
No significant difference seen in IBD events between patients treated with IL-17 inhibitors or placebo
Margin-Controlled Surgery Beneficial for Immunosuppressed With Cutaneous SCC
Risk for any poor outcomes and major poor outcomes reduced with MMS/PDEMA versus SEVMA
The Window Before HS Leaves Its Mark
In HS, what appears controlled in the moment may still be moving toward lasting structural change, raising an increasingly important question of when treatment...
Peripheral Globules, Related Lesion Dynamics Predict Outcomes in Melanocytic Nevi
Independent associations seen for increased pigmentation, faster growth, history of melanoma with clinically significant histopathologic end point
Upadacitinib Has Positive Benefit-Risk Profile for Severe Alopecia Areata
Proportion of adults, adolescents achieving SALT score of 20 or less significantly higher with upadacitinib versus placebo
New Melanoma Drug Based On Herpes Virus Granted FDA Accelerated Approval
The approval follows clinical trial data showing tumor shrinkage in 1 in 4 patients
24 of 1289